MENU
+Compare
CANC
ETF ticker: NASDAQ
AS OF
Aug 26, 04:55 PM (EDT)
Price
$26.78
Change
+$0.44 (+1.67%)
Net Assets
69.09M

CANC stock forecast, quote, news & analysis

The investment seeks to provide long-term growth... Show more

Category: #Health
CANC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for CANC with price predictions
Aug 25, 2025

CANC in -0.84% downward trend, declining for three consecutive days on August 20, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CANC declined for three days, in of 100 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 20, 2025. You may want to consider a long position or call options on CANC as a result. In of 29 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CANC just turned positive on August 15, 2025. Looking at past instances where CANC's MACD turned positive, the stock continued to rise in of 18 cases over the following month. The odds of a continued upward trend are .

CANC moved above its 50-day moving average on August 13, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CANC advanced for three days, in of 124 cases, the price rose further within the following month. The odds of a continued upward trend are .

CANC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 79 cases where CANC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Illumina (NASDAQ:ILMN).

Industry description

The investment seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Oncology ETF ETF is 42.65B. The market cap for tickers in the group ranges from 3.51M to 659.82B. LLY holds the highest valuation in this group at 659.82B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Oncology ETF ETF was 1%. For the same ETF, the average monthly price growth was -1%, and the average quarterly price growth was 5%. DAWN experienced the highest price growth at 9%, while AUTL experienced the biggest fall at -10%.

Volume

The average weekly volume growth across all stocks in the Tema Oncology ETF ETF was -7%. For the same stocks of the ETF, the average monthly volume growth was -3% and the average quarterly volume growth was -26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 79
Price Growth Rating: 55
SMR Rating: 77
Profit Risk Rating: 81
Seasonality Score: -18 (-100 ... +100)
View a ticker or compare two or three
CANC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co